CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.3200
+0.0124 (4.03%)
Jul 9, 2025, 1:51 PM EDT
CytoDyn Employees
CytoDyn had 9 employees as of May 31, 2024. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$951,667
Market Cap
384.88M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Elite Pharmaceuticals | 64 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
CytoDyn News
- 8 days ago - CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab - GlobeNewsWire
- 15 days ago - CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer - GlobeNewsWire
- 6 weeks ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga
- 7 weeks ago - CytoDyn Releases ESMO Breast Cancer Meeting Poster - GlobeNewsWire
- 2 months ago - CytoDyn highlights potential of lead drug against solid tumors with new data - Seeking Alpha
- 2 months ago - CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors - GlobeNewsWire
- 2 months ago - CytoDyn appoints Robert Hoffman as CFO - Seeking Alpha
- 2 months ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - Benzinga